In this study, to cope with GBM inter-tumor heterogeneity, we used multiple patient-derived GSC-ECLs with diverse genetic and phenotypic backgrounds9,10,43,44 and analyzed the relative contribution of the anti-apoptotic Bcl-2 family members in GSC viability and chemoresistance. This evidence concerns the gene BCL2 and glioblastoma.